Sat, 24 November 2012
Perhaps Rash SHOULD be a Critical Factor in Clarifying Who Benefits from an EGFR Inhibitor: The TOPICAL Study
Dr. H. Jack West reviews the TOPICAL study of Tarceva vs. placebo for marginal and poor PS patients with advanced NSCLC, which showed a clearly superior outcome with Tarceva in patients who developed a rash vs. those who don't.
Direct download: GRACEcastUC-005_Lung-Video_Rash_a_Factor_with_EGFR.m4v
Category:Lung-Cancer-Video -- posted at: 6:18pm PDT